Vnitr Lek 2005, 51(5):510-517

Acute myocarditis, prevalence, diagnosis and treatment in local hospital

M. Belicová*, J. Dvorský, Ľ. Vladár, M. Mokáň
I. interná klinika Jeseniovej lekárskej fakulty UK a Martinskej fakultnej nemocnice, Martin, Slovenská republika, prednosta prof. MUDr. Marián Mokáň, DrSc.

Clinical diagnosis of acute myocarditis is one of the greatest problems of contemporary cardiology, determined by wide clinical and laboratory polymorphysm of disease. Reliable, accurate diagnostic tests able to exclude or confirm diagnosis are not available yet.


Aim of the study:
Description of the prevalence, diagnosis and treatment of patients with acute myocarditis.


Patients:
From 1st July 2002 to 30th June 2003 12 patients (9 males) of age 24-49 years were hospitalised with the diagnosis of acute myocardidis.

Results:
8 patients had chest pain; these patients had changes on ECG. 4 patients had heart failure; these patients had changes on echocardiography. All patients had elevation of level of troponin T and 50% of them elevation of level of creatinkinase. All patients had fever.

Conclusion:
Acute myocarditis on the ECG was manifested by changes of the repolarization stage ST-T which simulated acute non Q and Q myocardial infarction or pericarditis. Echocardiography reveal localized kinetic disorders with dilated or not dilated chambers of heart.

Keywords: myocarditis; cardiomyopathy; cytokines; heart failure

Received: February 11, 2004; Accepted: August 23, 2004; Published: May 1, 2005  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Belicová M, Dvorský J, Vladár Ľ, Mokáň M. Acute myocarditis, prevalence, diagnosis and treatment in local hospital. Vnitr Lek. 2005;51(5):510-517.
Download citation

References

  1. Caforio AL, Mahon NJ, Mckenna WJ. Cardiac autoantibodies to myosin and other heart-specific autoantigens in myocarditis and dilated cardiomyopathy. Autoimmunity 2001; 34(3): 199-204. Go to original source... Go to PubMed...
  2. Campana C, Monti L, Arbustini E et al. Clinicopathological correlates can predict acute myocarditis in patients with recent-onset heart failure: preliminary data. Ital Heart J 2002; 3(3): 188-193. Go to PubMed...
  3. Cappola TP, Felker GM, Kao WH et al. Pulmonary hypertension and risk of death in cardiomyopathy: patients with myocarditis are at higher risk. Circulation 2002; 105(14): 1663-1668. Go to original source... Go to PubMed...
  4. Dong R. Verapamil ameliorates the clinical pathological course of murine myocarditis. J Clin Invest 1992; 90: 2022-2030. Go to original source... Go to PubMed...
  5. Furukawa Y, Kobuke K, Matsumori A. Role of cytokines in autoimmune myocarditis and cardiomyopathy. Autoimmune 2001; 34(3): 165-168. Go to original source... Go to PubMed...
  6. Gregor P. Myokarditidy. Vnitř Lék 2000; 46(11): 801-807. Go to PubMed...
  7. Gregor P. Význam elektrokardiografie u kardiomyopatií. Vnitř Lék 2002; 48(Suppl 1): 64-66. Go to PubMed...
  8. Hill SL, Rose NR. The transition from viral to autoimmune myocarditis. Autoimmunity 2001; 34(3): 169-176. Go to original source... Go to PubMed...
  9. Kvasnička J, Tušl Z, Ceral J et al. Pruměrované EKG v dlouhodobém sledování nemocného s fulminantnou myokarditídou. Vnitř Lék 2002; 48(Suppl 1): 213-215. Go to original source... Go to PubMed...
  10. Maisch B, Ristic AD, Hufnagel G et al. Pathophysiology of viral myocarditis. The role of humoral immune response. Cardiovacs Pathol 2002; 11(2): 112-122. Go to original source... Go to PubMed...
  11. Rezkalla S. Treatment of viral myocarditis with focus on captopril. Am J Cardiol 1996; 77: 634-637. Go to original source... Go to PubMed...
  12. Sherry B. The role of interferon regulatory factors in the cardiac response to viral infection. Viral Immunol 2002; 15(1): 17-28. Go to original source... Go to PubMed...
  13. Shiono T, Kodama M, Hanawa H et al. Suppression of myocardial inflammation using sumarin, a growth factor blocker. Circ J 2002; 66(4): 385-389. Go to original source... Go to PubMed...
  14. Spodick DH. Myopericarditis/Perimyocarditis. In: Braunwald E. Heart disease. Philadelphia: WB Saunders 2001: 1836-1838.
  15. Šochman J. Disciplína: akútna nekróza myokardu. Cor Vasa 2002; 44(10): 392-395.
  16. Špinarová L, Toman J. Genetika dilatační kardiomyopatie a myopatií. Cor Vasa 2003; 45(6): 329-332.
  17. Tabet JY, Lopes ME, Champagne S et al. Inflammation, cytokinines and antiinflammatory therapies in heart failure. Arch Mal Coeur Vaiss 2002; 95(3): 204-212. Go to PubMed...
  18. Tedeschi A, Airaghi L, Giannini S et al. High-dose intravenous immunoglobulin in the treatment of acute myocarditis. A case report and review of the literature. J Intern Med 2002; 251(2): 169-173. Go to original source... Go to PubMed...
  19. Wynne J. Myocarditis. In: Braunwald E. Heart disease. Philadelphia: WB Saunders 2001: 1783-1806.
  20. Yoshida A, Kand T, Tanaka T et al. Interleukin - 18 reduces expression of cardiac tumor necrosis factor-alpha and atrial natriuretic peptide in a murine model of viral myocarditis. Life Sci 2002; 70(11): 1225-1234. Go to original source... Go to PubMed...




Vnitřní lékařství

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.